



PORTEC-3 trial

Trial setting: Randomised trial of adjuvant pelvic radiation therapy with or without concurrent and adjuvant chemotherapy for women with high-risk endometrial cancer

Study Design: International Intergroup trial

Sponsor(s): Dutch Cancer Society, CRUK (UK), NHMRC (ANZGOG), IMA (MaNGO), CCSRI (CCTG), local site fund (Fedegyn)

Final No. of patients: 686

Timeline (first patient – trial closing): 2006-2016

Publications: Toxicity and QOL: de Boer et al, Lancet Oncology 2016. Final results presented at ASCO 2017

Planned publications: Pathology review (submitted), final results (submitted), RT QA (TROG)

Substudies: completed (with publication): patient preferences substudy (ANZGOG), RT benchmarking (TROG/ANZGOG); planned translational work (TransPORTEC)

